Biologicals in osteoporosis: Teriparatide and parathyroid hormone in women and men

Current Osteoporosis Reports

Volumn 8, Issue 3, 2010, Pages 154-161

  Devogelaer, Jean Pierre ^a   Boutsen, Yves ^b   Manicourt, Daniel H ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Alternate therapy; Bisphosphonate; Bone mineral density; Combined therapy; Fractures; Isolated therapy; Males; Markers of bone remodeling; Osteoporosis; Parathyroid hormone; Postmenopausal females; Raloxifene; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; ETIDRONIC ACID; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN[1-36]; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN C PROTEINASE; PROLYLPROLYL PARATHYROID HORMONE[1-34][11 ARGININE] PROLYLPROLYLASPARTATE; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

BACKACHE; BONE DENSITY; BONE FRAGILITY; BONE TURNOVER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; FRACTURE HEALING; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LOW DRUG DOSE; MEDICAL HISTORY; MEN'S HEALTH; MONOTHERAPY; MORPHOMETRICS; NAUSEA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION; VERTEBRA FRACTURE; VOMITING; WOMEN'S HEALTH; DRUG EFFECTS; FEMALE; HOMEOSTASIS; MALE; METABOLISM; MIDDLE AGED;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; TERIPARATIDE;

EID: 77955983172     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0024-1     Document Type: Review

References (61)

1. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis [no authors listed]. Am J Med 1991, 90:107-110.
2. NB Watts C Cooper R Lindsay, et al. 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 261 10.1385/JCD:7:3:255 15319494
3. SR Cummings DB Karpf F Harris, et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289 10.1016/S0002-9343(01)01124-X 1:CAS:528:DC%2BD38XhvVWkurk%3D 11893367
4. S Sarkar BH Mitlak M Wong, et al. 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1 10 10.1359/jbmr.2002.17.1.1 1:CAS:528:DC%2BD38XktFyisg%3D%3D 11771654
5. O Bruyere C Roux J Detilleux, et al. 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate J Clin Endocrinol Metab 92 3076 3081 10.1210/jc.2006-2758 1:CAS:528:DC%2BD2sXptl2hsb0%3D 17566094
6. H Selye 1932 On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol Endocrinology 16 547 558 10.1210/endo-16-5-547 1:CAS:528:DyaA3sXisleqsQ%3D%3D
7. J Reeve R Hesp D Williams, et al. 1976 Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis Lancet 1 1035 1038 10.1016/S0140-6736(76)92216-9 1:STN:280:DyaE287ntlehtA%3D%3D 57447
8. J Reeve PJ Meunier JA Parsons, et al. 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial Br Med J 280 1340 1344 10.1136/bmj.280.6228.1340 1:STN:280:DyaL3c3it1SisQ%3D%3D 6992932
9. J Reeve UM Davis R Hesp, et al. 1990 Treatment of osteoporosis with human parathyroid hormone and observations on the effects of sodium fluoride therapy Br Med J 301 314 318 10.1136/bmj.301.6747.314 1:STN:280:DyaK3czms1Omug%3D%3D
10. J Reeve JN Bradbeer M Arlot, et al. 1991 hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses Osteoporosis Int 1 162 170 10.1007/BF01625448 1:STN:280:DyaK387mtlKmtA%3D%3D
11. DM Slovik DI Rosenthal SH Doppelt, et al. 1986 Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1, 25-dihydroxyvitamin D J Bone Miner Res 1 377 381 10.1002/jbmr.5650010411 1:STN:280:DyaL1M%2Fit1aksg%3D%3D 3503551
12. PD Delmas P Vergnaud ME Arlot, et al. 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16 603 610 10.1016/8756-3282(95)00113-R 1:CAS:528:DyaK2MXmsVKjurs%3D 7669436
13. V Shen DW Dempster R Birchman, et al. 1993 Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol J Clin Invest 91 2479 2487 10.1172/JCI116483 1:CAS:528:DyaK3sXkvVKls7k%3D 8514860
14. RM Neer CD Arnaud JR Zanchetta, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 10.1056/NEJM200105103441904 1:CAS:528:DC%2BD3MXktVSgsbw%3D 11346808
15. JL Vahle GG Long G Sandusky, et al. 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose Toxicol Pathol 32 426 438 10.1080/01926230490462138 1:CAS:528: DC%2BD2cXlslSgtro%3D 15204966
16. NB Watts PD Miller LA Kohlmeier, et al. 2009 Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment J Bone Miner Res 24 1125 1131 10.1359/jbmr.081256 1:CAS:528:DC%2BD1MXmvFyjt70%3D 19113918 Losing BMD when on TPTD therapy does not necessarily mean increase in fracture risk
17. MC Nevitt P Chen RK Dore, et al. 2006 Reduced risk of back pain following teriparatide treatment: a meta-analysis Osteoporos Int 17 273 280 10.1007/s00198-005-2013-2 16142502
18. P Aspenberg HK Genant T Johansson, et al. 2010 Teriparatide for acceleration of fracture repair in humans: A prospective, randomized double-blind study of 102 postmenopausal women with distal radial fractures J Bone Miner Res 25 404 414 1:CAS:528:DC%2BC3cXksl2ksLg%3D 19594305 TPTD therapy could help to accelerate the fracture repair in humans
19. M Tagil MM McDonald A Morse, et al. 2010 Intermittent PTH (1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures Bone 46 852 859 10.1016/j.bone.2009.11.009 19922821
20. HG Bone D Hosking JP Devogelaer, et al. 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199 10.1056/NEJMoa030897 1:CAS:528:DC%2BD2cXit12rsLc%3D 15028823
21. JM Kaufman E Orwoll S Goemaere, et al. 2005 Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy Osteoporos Int 16 510 516 10.1007/s00198-004- 1713-3 1:CAS:528:DC%2BD2MXlsFSrsr8%3D 15322742
22. JS Finkelstein JJ Wyland BZ Leder, et al. 2009 Effects of teriparatide retreatment in osteoporotic men and women J Clin Endocrinol Metab 94 2495 2501 10.1210/jc.2009-0154 1:CAS:528:DC%2BD1MXosl2ks7Y%3D 19401368 There is a possibility of having several courses of TPTD therapy separated by weaning periods.
23. F Cosman JW Niewes M Zion, et al. 2009 Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate J Bone Miner Res 24 1110 1115 10.1359/jbmr.081250 19113926
24. R Eastell T Nickelsen F Marin, et al. 2009 Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS) J Bone Miner Res 24 726 736 10.1359/jbmr.081215 1:CAS:528:DC%2BD1MXksF2ksL0%3D 19049337
25. BZ Leder RM Neer JJ Wyland, et al. 2009 Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis J Clin Endocrinol Metab 94 2915 2921 10.1210/jc.2008-2630 1:CAS:528: DC%2BD1MXpvFGntLg%3D 19435827 Contrary to postmenopausal women, in eugonadal males, there is no bone loss after stopping TPTD
26. R Lindsay WH Scheele R Neer, et al. 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2024 2030 10.1001/archinte.164.18.2024 15477438
27. F Cosman S Nieves L Woelfert, et al. 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal J Bone Miner Res 16 925 931 10.1359/jbmr.2001.16.5.925 1:CAS:528:DC%2BD3MXjs1Wjuro%3D 11341338
28. JS Finkelstein A Hayes JL Hunzelman, et al. 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 1216 1226 10.1056/NEJMoa035725 1:CAS:528:DC%2BD3sXns1Kmsrs%3D 14500805
29. ET Middleton SA Steel SM Doherty 2007 The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice Calcif Tissue Int 81 335 340 10.1007/s00223-007-9066-5 1:CAS:528:DC%2BD2sXht1Oks77J 17938845
30. BM Obermayer-Pietsch F Marin EV McCloskey, et al. 2008 Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 23 1591 1600 10.1359/jbmr.080506 1:CAS:528:DC%2BD1cXht1OntLfM 18505369
31. B Ettinger J San Martin G Crans I Pavo 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 745 751 10.1359/JBMR.040117 1:CAS:528:DC%2BD2cXktFGksrk%3D 15068497
32. PD Miller PD Delmas R Lindsay, et al. 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate J Clin Endocrinol Metab 93 3785 3793 10.1210/jc.2008-0353 1:CAS:528: DC%2BD1cXht1Gmur%2FN 18682511 Contrary to what has been written, there is apparently no blunting effect of TPTD by previous BP therapy
33. S Boonen F Marin B Obermayer-Pietsch, et al. 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis J Clin Endocrinol Metab 93 852 860 10.1210/jc.2007-0711 1:CAS:528:DC%2BD1cXjsFynurg%3D 18160462
34. C Keel ME Kraenzlin CA Kraenzlin, et al. 2010 Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice J Bone Miner Metab 28 68 76 10.1007/s00774-009-0101-7 1:CAS:528:DC%2BC3cXjtlChug%3D%3D 19633810 It is therefore not necessary to have a washing-out period from BPs before starting TPTD
35. F Cosman RA Wermers C Recknor, et al. 2009 Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent J Clin Endocrinol Metab 94 3772 3780 10.1210/jc.2008-2719 1:CAS:528:DC%2BD1MXht12ru7jO 19584192
36. F Cosman J Nieves M Zion, et al. 2005 Daily and cyclic parathyroid hormone in women receiving alendronate N Engl J Med 353 566 575 10.1056/NEJMoa050157 1:CAS:528:DC%2BD2MXnsVaqsbY%3D 16093465
37. S Adami 2008 San Martin J, Munoz-Torres M, et al.: Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis Osteoporos Int 19 87 94 10.1007/s00198-007-0485-y 1:CAS:528:DC%2BD1cXislGjsbc%3D 17938984
38. F Cosman JW Nieves M Zion, et al. 2008 Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy Osteoporos Int 19 529 535 10.1007/s00198-007-0475-0 1:CAS:528: DC%2BD1cXkslOksLY%3D 17929072
39. ES Kurland F Cosman DJ McMahon, et al. 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers J Clin Endocrinol Metab 85 3069 3076 10.1210/jc.85.9.3069 1:CAS:528:DC%2BD3cXmsVKrurk%3D 10999788
40. ES Orwoll WH Scheele S Paul, et al. 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 9 17 10.1359/jbmr.2003.18.1.9 1:CAS:528:DC%2BD3sXltFKmtw%3D%3D 12510800
41. JP Devogelaer 2006 Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach Rheum Dis Clin N Am 32 733 757 10.1016/j.rdc.2006.09.001
42. NE Lane S Sanchez GW Modin, et al. 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial J Clin Invest 102 1627 1633 10.1172/JCI3914 1:CAS:528: DyaK1cXmvVynsL0%3D 9788977
43. NE Lane S Sanchez GW Modin, et al. 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial J Bone Miner Res 15 944 951 10.1359/jbmr.2000.15.5.944 1:CAS:528:DC%2BD3cXjt1CrsL0%3D 10804025
44. KG Saag E Shane S Boonen, et al. 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2028 2039 10.1056/NEJMoa071408 1:CAS:528:DC%2BD2sXhtlWis7rP 18003959
45. KG Saag JR Zanchetta J-P Devogelaer, et al. 2009 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis. Thirty-six-month results of a randomized, double-blind, controlled trial Arthritis Rheum 60 3346 3355 10.1002/art.24879 1:CAS:528:DC%2BD1MXhsFentLzO 19877063
46. JP Devogelaer RA Adler C Recknor, et al. 2010 Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis J Rheumatol 37 141 148 10.3899/jrheum.090411 1:CAS:528:DC%2BC3cXitVajtL4%3D 19918047
47. R Eastell P Chen KG Saag, et al. 2010 Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate Bone 46 929 934 10.1016/j.bone.2009.12.021 1:CAS:528: DC%2BC3cXjs1aktrc%3D 20060078
48. AB Hodsman DA Hanley MP Ettinger, et al. 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis J Clin Endocrinol Metab 88 5212 5220 10.1210/jc.2003-030768 1:CAS:528:DC%2BD3sXptVyns7k%3D 14602752
49. SL Greenspan HG Bone MP Ettinger, et al. 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial Ann Intern Med 146 326 339 17339618
50. I Fogelman JN Fordham WD Fraser, et al. 2008 Parathyroid hormone (1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy Calcif Tissue Int 83 85 92 10.1007/s00223-008-9152-3 1:CAS:528:DC%2BD1cXhtVyisr7F 18626566
51. RR Recker SP Bare SY Smith, et al. 2009 Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84 Bone 44 113 119 10.1016/j.bone.2008. 09.019 1:CAS:528:DC%2BD1cXhsFahtLjJ 18983947
52. DM Black ML Bouxsein L Palermo, et al. 2008 Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling J Clin Endocrinol Metab 93 2166 2172 10.1210/jc.2007-2781 1:CAS:528: DC%2BD1cXntFamtrY%3D 18349061
53. DM Black JP Bilezikian KE Ensrud, et al. 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 555 565 10.1056/NEJMoa050336 1:CAS:528:DC%2BD2MXnsVWmtb0%3D 16093464
54. P Garnero DC Bauer E Mareau, et al. 2008 Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PATH study J Bone Miner Res 23 1442 1448 10.1359/jbmr.080413 1:CAS:528:DC%2BD1cXhtFSlurvL 18442311
55. RR Recker F Marin S Ish-Shalom, et al. 2009 Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis J Bone Miner Res 24 1358 1368 10.1359/jbmr.090315 1:CAS:528:DC%2BD1MXhtFaitrvF 19338452 This paper shows the differing mechanisms of action between two promotors of bone formation
56. J Feng Y Liu Y Xing, et al. 2009 A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis Peptides 30 1173 1180 10.1016/j.peptides.2009.02.013 1:CAS:528:DC%2BD1MXmsVSgt7k%3D 19463752
57. F Cosman LE Lane MA Bolognese, et al. 2010 Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women J Clin Endocrinol Metab 95 151 158 10.1210/jc.2009-0358 1:CAS:528: DC%2BC3cXhtVGhs7c%3D 19858319 This paper discusses a new mode of administration of PTH
58. M Ameri PE Daddona YF Maa 2009 Demonstrated solid-state stability of parathyroid hormone PTH (1-34) coated on a novel transdermal microprojection delivery system Pharm Res 26 2454 2463 10.1007/s11095-009-9960-9 1:CAS:528:DC%2BD1MXhtVygsb3N 20183917
59. M Everhart-Caye SE Inzucchi J Guinness-Henry, et al. 1996 Parathyroid hormone (PTH)-related protein (1-36) is equipotent with PTH (1-34) in humans J Clin Endocrinol Metab 81 199 208 10.1210/jc.81.1.199 1:CAS:528: DyaK28XkvVyrsg%3D%3D 8550752
60. MJ Horwitz MB Tedesco A Garcia-Ocana, et al. 2010 Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose J Clin Endocrinol Metab 95 1279 1287 10.1210/jc.2009-0233 1:CAS:528:DC%2BC3cXjs1Kqt7Y%3D 20061412
61. S Kumar CJ Matheny SJ Hoffman, et al. 2010 An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation Bone 46 534 542 10.1016/j.bone.2009.09.028 1:CAS:528:DC%2BC3cXpslejug%3D%3D 19786130